356 related articles for article (PubMed ID: 15716361)
41. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.
Tofaris GK; Layfield R; Spillantini MG
FEBS Lett; 2001 Nov; 509(1):22-6. PubMed ID: 11734199
[TBL] [Abstract][Full Text] [Related]
42. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
43. A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
Giorgi FS; Bandettini di Poggio A; Battaglia G; Pellegrini A; Murri L; Ruggieri S; Paparelli A; Fornai F
J Neural Transm Suppl; 2006; (70):105-9. PubMed ID: 17017516
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse.
Wang ZH; Zhang JL; Duan YL; Zhang QS; Li GF; Zheng DL
Biomed Pharmacother; 2015 Aug; 74():252-6. PubMed ID: 26349993
[TBL] [Abstract][Full Text] [Related]
45. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
Liang Y; Li S; Zou Q; Su B
Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
[TBL] [Abstract][Full Text] [Related]
46. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation.
Thomas B; Mandir AS; West N; Liu Y; Andrabi SA; Stirling W; Dawson VL; Dawson TM; Lee MK
PLoS One; 2011 Jan; 6(1):e16706. PubMed ID: 21304957
[TBL] [Abstract][Full Text] [Related]
47. Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.
Pattarini R; Rong Y; Shepherd KR; Jiao Y; Qu C; Smeyne RJ; Morgan JI
Neuroscience; 2012 Jul; 214():84-105. PubMed ID: 22542874
[TBL] [Abstract][Full Text] [Related]
48. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
49. Motor Neurons Pathology After Chronic Exposure to MPTP in Mice.
Vivacqua G; Biagioni F; Busceti CL; Ferrucci M; Madonna M; Ryskalin L; Yu S; D'Este L; Fornai F
Neurotox Res; 2020 Feb; 37(2):298-313. PubMed ID: 31721049
[TBL] [Abstract][Full Text] [Related]
50. Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse.
Heng Y; Li YY; Wen L; Yan JQ; Chen NH; Yuan YH
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364248
[TBL] [Abstract][Full Text] [Related]
51. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Rideout HJ; Lang-Rollin IC; Savalle M; Stefanis L
J Neurochem; 2005 Jun; 93(5):1304-13. PubMed ID: 15934949
[TBL] [Abstract][Full Text] [Related]
52. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function.
Snyder H; Mensah K; Theisler C; Lee J; Matouschek A; Wolozin B
J Biol Chem; 2003 Apr; 278(14):11753-9. PubMed ID: 12551928
[TBL] [Abstract][Full Text] [Related]
53. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.
McCormack AL; Mak SK; Shenasa M; Langston WJ; Forno LS; Di Monte DA
J Neuropathol Exp Neurol; 2008 Aug; 67(8):793-802. PubMed ID: 18648323
[TBL] [Abstract][Full Text] [Related]
54. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y; Kajiyama S; Saji H
Nucl Med Biol; 2006 Jan; 33(1):37-42. PubMed ID: 16459257
[TBL] [Abstract][Full Text] [Related]
55. Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice.
Carvalho AN; Marques C; Rodrigues E; Henderson CJ; Wolf CR; Pereira P; Gama MJ
Mol Neurobiol; 2013 Apr; 47(2):662-72. PubMed ID: 23129554
[TBL] [Abstract][Full Text] [Related]
56. Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice.
Nakajima K; Minematsu M
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):70-4. PubMed ID: 16637233
[TBL] [Abstract][Full Text] [Related]
57. beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein.
Snyder H; Mensah K; Hsu C; Hashimoto M; Surgucheva IG; Festoff B; Surguchov A; Masliah E; Matouschek A; Wolozin B
J Biol Chem; 2005 Mar; 280(9):7562-9. PubMed ID: 15591046
[TBL] [Abstract][Full Text] [Related]
58. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability.
Chen Q; Thorpe J; Keller JN
J Biol Chem; 2005 Aug; 280(34):30009-17. PubMed ID: 15941712
[TBL] [Abstract][Full Text] [Related]
59. Effect of Anti-Glutamate Antibodies in Modeled Parkinsonian Syndrome.
Kucheryanu VG; Vetrile LA; Zakharova IA; Voronina NA
Bull Exp Biol Med; 2020 Aug; 169(4):431-434. PubMed ID: 32889565
[TBL] [Abstract][Full Text] [Related]
60. Ubiquitin Subproteome of Brain Mitochondria and Its Changes Induced by Experimental Parkinsonism and Action of Neuroprotectors.
Buneeva OA; Medvedeva MV; Kopylov AT; Medvedev AE
Biochemistry (Mosc); 2019 Nov; 84(11):1359-1374. PubMed ID: 31760923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
